Eventide Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Eventide Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.23M	Buy	+900,000	New	+$4.57M	0.07%	170
2017 Q3	–	Sell	-150,000	Closed	-$2.33M	–	137
2017 Q2	$2.33M	Hold	150,000	–	–	0.14%	93
2017 Q1	$2.59M	Hold	150,000	–	–	0.17%	89
2016 Q4	$1.65M	Hold	150,000	–	–	0.11%	98
2016 Q3	$2.35M	Hold	150,000	–	–	0.14%	92
2016 Q2	$1.53M	Hold	150,000	–	–	0.09%	100
2016 Q1	$1.94M	Buy	150,000 +50,000	+50%	+$694K	0.11%	103
2015 Q4	$2.09M	Buy	+100,000	New	+$1.58M	0.1%	99

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eventide Asset Management's CTMX Position: Q1 2026 in Review

Eventide Asset Management opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 900,000 shares worth $4.23M. The stake represents 0.07% of the portfolio and ranks #170 among its holdings. This is a return to the name: Eventide Asset Management previously reported a position in CTMX as recently as Q2 2017.

Eventide Asset Management first reported a position in CTMX in Q4 2015 and has held it in 8 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

Eventide Asset Management held 900,000 shares of CytomX Therapeutics worth $4.23M as of Q1 2026.
CytomX Therapeutics was a new Eventide Asset Management position in Q1 2026.
CytomX Therapeutics made up 0.07% of Eventide Asset Management's portfolio in Q1 2026, its #170 holding.
Eventide Asset Management first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 8 quarters since.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.